Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Reiterates Buy Rating and $21 PT on Ironwood Pharmaceuticals (IRWD) Following 4Q16 Results
February 22, 2017 5:52 AM ESTMizuho Securities analyst Irina Koffler reiterates Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), as the company reported 2016 fourth quarter revenues and EPS figures above consensus.
Koffler comments, "4Q:16 beat was great but not surprising since consensus largely omitted a $15M milestone associated with regulatory approval in Japan: IRWD reported 4Q:16 revenues of $87.5M... More
